AKAM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Akamai Technologies Inc (AKAM) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown promising developments in AI and cloud infrastructure, the recent financial performance indicates declining profitability, and technical indicators do not suggest a strong entry point. Additionally, the lack of a clear buy signal from Intellectia Proprietary Trading Signals further supports a cautious approach.
The MACD is negative and contracting (-0.403), RSI is neutral at 51.066, and moving averages are converging, indicating no clear trend. The stock is trading near a resistance level (R1: 103.433) with support at 94.379, suggesting limited upside in the short term.
Akamai signed a $200 million service agreement for high-performance AI compute, showcasing its growth in AI and cloud infrastructure.
Recent acquisition of NVIDIA GPUs enhances AI computational capabilities and positions the company well for future growth in the AI sector.
Hedge funds are significantly increasing their holdings, indicating institutional confidence.
Financial performance in Q4 2025 showed a significant drop in net income (-39.19% YoY) and EPS (-36.26% YoY), raising concerns about profitability.
Analysts have mixed ratings, with some highlighting concerns over higher investments impacting margins and a slowdown in the security segment.
Technical indicators and stock trend analysis suggest limited short-term upside.
In Q4 2025, revenue increased by 7.35% YoY to $1.09 billion, but net income dropped by 39.19% YoY to $85.07 million. EPS also declined by 36.26% YoY to 0.58, and gross margin fell slightly to 56.12%. While revenue growth is positive, declining profitability is a concern.
Analysts have mixed views. Outperform ratings from firms like Raymond James, Baird, and Evercore ISI highlight growth potential in compute and security. However, concerns about higher investments and a slowdown in the security segment are noted by firms like Piper Sandler and TD Cowen. Price targets range from $76 (Goldman Sachs, Sell) to $120 (Susquehanna, Positive).
